QS
Qin, S.
2 yayın · 5 atıf · 2023–2023
Yayın
2
Atıf
5
Yıllar
1
Yayınlar
| Başlık | Yıl | Tip | Atıf |
|---|---|---|---|
|
The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
|
2023 | Meeting Abstract | 0 |
|
Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/ GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study
|
2023 | Meeting Abstract | 5 |